Fruquintinib with or without liver-directed chemo for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to the liver (confirmed by scan or biopsy).
- You have at least one tumor that can be measured on a scan.
- If cancer is outside the liver, it must be limited (small spots in the lung or lymph nodes only).
- Your cancer has grown within 3 months of your last standard treatment, or you couldn't tolerate that treatment.
- Your liver and kidney function are good (based on blood tests), and you are in generally good health (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
This trial is testing a new combination of two oral cancer drugs (fruquintinib and S-1) in people with metastatic colorectal cancer who have already had at least one prior chemotherapy. The goal is to see if this combination helps shrink or slow the growth of tumors.
This trial tests a combination of two drugs and a liver-directed therapy for people with advanced colorectal cancer that has spread to the liver. It aims to see if this approach can help when standard first-line treatment has stopped working.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This study tests a combination of an immunotherapy drug, a targeted therapy, and a type of low-dose radiation before standard third-line treatment in patients with colorectal cancer that has spread to the liver. The goal is to see if this approach is safe and helps shrink tumors or slow cancer growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.